Home

Research and Development Advisors

The respected experts that comprise Tengion's research and development advisors leverage their years of experience to provide scientific insight and maintain the highest standards.

  • Steve Badylak, M.D. Ph.D., D.V.M., Professor and Director of Center for Pre-Clinical Tissue Engineering, University of Pittsburgh

    Dr. Badylak is currently a research professor in the Department of Surgery and director of the Center for Pre-Clinical Tissue Engineering within the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. In 1976, he received his D.V.M. from Purdue University and he completed his M.S. in Clinical Pathology from Purdue University in 1978. Dr. Badylak also holds a Ph.D. in Anatomic Pathology from Purdue University (1981) and graduated with highest honors with a M.D. from Indiana University Medical School in 1985. Prior to his post graduate training, Dr. Badylak practiced veterinary medicine at a mixed animal practice in Glenwood, Illinois and in Hobart, Indiana. Dr. Badylak began his academic career at Purdue University as an Assistant Research Scholar at the Hillenbrand Biomedical Engineering Center in 1983. At Purdue University, Dr. Badylak held a variety of positions including Postdoctoral Research Associate (1985), Associate Research Scholar (1988) and the Director of the Hillenbrand Biomedical Engineering Center from (1993-1998). Dr. Badylak held a dual appointment as an Associate Professor within the Department of Veterinary Physiology and Pharmacology and also served as the Head Team Physician for the Athletic Department for 16 years (1985-2001). Most recently, Dr. Badylak served as Senior Research Scientist within the Department of Biomedical Engineering at Purdue University and Adjunct Associate Professor of Pathology and Laboratory Medicine at the Indiana University School of Medicine. Dr. Badylak has either chaired or been a member of the Scientific Advisory Board to several major medical device companies including DePuy, Cook Biotech, Genesis Orthopaedics, Sentron Medical Ventures, and ACell.

  • Arthur Caplan, Ph.D., Professor of Bioethics and Chair of the Department of Medical Ethics / Director of Center of Bioethics, University Of Pennsylvania

    Dr. Caplan is a Professor of Bioethics and Chair of the Department of Medical Ethics and the Director of the Center for Bioethics at the University of Pennsylvania in Philadelphia. Prior to coming to Penn in 1994, Dr. Caplan taught at the University of Minnesota, the University of Pittsburgh, and Columbia University. He was the Associate Director of the Hastings Center from 1984-1987. Caplan is the author or editor of twenty-five books and over 500 papers in refereed journals of medicine, science, philosophy, bioethics and health policy. He writes a regular column on bioethics for MSNBC.com. He is a frequent guest and commentator on National Public Radio, CNN, MSNBC, the New York Times, Washington Post, Philadelphia Inquirer and many other media outlets. He has served on a number of national and international committees including as the Chair of the Advisory Committee to the United Nations on Human Cloning, the Chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability, a member of the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the American Chemistry Council and the special advisory panel to the National Institutes of Mental Health on human experimentation on vulnerable subjects. He is a member of Dupont's biotechnology advisory panel and has consulted with many corporations and consumer organizations. Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association, Person of the Year-2001 from USA Today, one of the fifty most influential people in American health care by Modern Health Care magazine and one of the ten most influential people in America in biotechnology by the National Journal. He holds six honorary degrees from colleges and medical schools. He is a fellow of the Hastings Center, the NY Academy of Medicine, the College of Physicians of Philadelphia and the American Association for the Advancement of Science. Born in Boston, Caplan did his undergraduate work at Brandeis University, and did his graduate work at Columbia University where he received a Ph.D. in the history and philosophy of science in 1979.

  • Victor Dzau, M.D., Chancellor, Health Affairs, Duke University & President & CEO Duke University Health System

    Dr. Dzau became chancellor for health affairs at Duke University and president and CEO of the Duke University Health System on July 1, 2004. Dr. Dzau most recently served as the Hersey Professor of the Theory and Practice of Physic (Medicine) at Harvard Medical School, Chairman of the Department of Medicine at Brigham and Women's Hospital, and Physician-in-Chief and Director of Research at Brigham and Women's Hospital, Boston. Dr. Dzau's academic interests are in cardiovascular translational research and mission-based education. His laboratory has studied the molecular and genetic mechanisms of cardiovascular disease and applied genomic and gene transfer technologies to develop novel therapeutic approaches. A genetically modified coronary bypass graft developed by Dr. Dzau is being evaluated in a clinical trial. The recipient of many awards and honors, he received the first Hatter Award from the Medical Research Council of South Africa in 2000. Most recently, he was awarded the prestigious Gustav Nylin Medal from the Swedish Royal College of Medicine and the Swedish Cardiology Society, and the Novartis Award for Hypertension Research of the American Heart Association (AHA). Dr. Dzau sits on numerous committees and advisory boards, including the Executive Committee of The Academy at Harvard Medical School (of which he is a founding member) and the boards of Brigham and Women's Hospital and the Harvard Clinical Research Institute. He has been elected to the Institute of Medicine, National Academy of Science (USA) and the European Academy of Science and Arts. Previous Chairman of the National Institutes of Health (NIH) Cardiovascular Disease Advisory Committee, he now sits on the Advisory Committee to the Director of the NIH. In 1999, he became Editor-in-Chief for the American Physiological Society's new journal, Physiological Genomics. A founding member of the Society of Vascular Medicine and Biology, Dr. Dzau was Editor-in-Chief of the Journal of Vascular Medicine and Biology. After receiving his MD from McGill University in Montreal, Dr. Dzau underwent postgraduate training at Harvard Medical School.

  • Ben Humphreys, M.D., Ph.D., Assistant Professor of Medicine, Harvard Medical School, Principal Faculty Member of the Harvard Stem Cell Institute and Co-Director of the Harvard Stem Cell Institute Kidney Program

    Dr. Humphreys is an Assistant Professor of Medicine at Harvard Medical School and Principal Faculty Member of the Harvard Stem Cell Institute and Co-Director of the Harvard Stem Cell Institute Kidney Program. He received a bachelor’s degree from Harvard College and M.D. and Ph.D. degrees from Case Western Reserve University. Dr. Humphreys completed a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Nephrology at Brigham and Women’s Hospital in Boston. He is the recipient of a Harvard Stem Cell Institute Seed Grant, the National Kidney Foundation Young Investigator Award and the American Society of Nephrology Gottschalk Research Scholar Award. He investigates kidney repair in order to translate this knowledge into therapies for patients with kidney disease.

  • Robert Nerem, Ph.D., Director, Parker H. Petit Institute for Bioengineering & Bioscience, Georgia Tech University

    Dr. Nerem joined Georgia Tech in 1987 as the Parker H. Petit Distinguished Chair for Engineering in Medicine. He currently serves as the Director of the Parker H. Petit Institute for Bioengineering and Bioscience. In addition he serves as the Director of the Georgia Tech/Emory Center (GTEC) for the Engineering of Living Tissues, an NSF-funded Engineering Research Center, and he is a part-time Senior Advisor for Bioengineering in the new National Institute for Biomedical Imaging and Bioengineering at the National Institutes of Health. He received his Ph.D. in 1964 from Ohio State University and joined the faculty there in the Department of Aeronautical and Astronautical Engineering, being promoted to Professor in 1972 and serving from 1975-1979 as Associate Dean for Research in the Graduate School. From 1979 to 1986 he was Professor and Chairman of the Department of Mechanical Engineering at the University of Houston. Dr. Nerem is the author of more than 200 publications. Dr. Nerem serves on the scientific advisory board of AtheroGenics, Inc. ( Alpharetta, GA). Research interests are in bioengineering and include atherosclerosis, biomechanics, cardiovascular devices, cellular engineering, vascular biology, and tissue engineering.

  • Buddy Ratner, Ph.D., Professor of Bioengineering and Chemical Engineering, University of Washington

    Dr. Ratner is the Michael L. and Myrna Darland Endowed Chair in Technology Commer-cialization, Professor of Bioengineering and Professor of Chemical Engineering at the University of Washington and received his Ph.D. (1971) in polymer chemistry from the Polytechnic Institute of Brooklyn. From 1985-1996 he directed the National ESCA and Surface Analysis Center for Biomedical Problems (NESAC/BIO). In 1996, he assumed the directorship of University of Washington Engineered Biomaterials (UWEB), an NSF Engineering Research Center. He is the editor of Journal of Undergraduate Research in BioEngineering, a past president of the Society For Biomaterials and author over 300 scholarly works. Ratner is a fellow of the American Institute of Medical and Biological Engineering (AIMBE), the American Vacuum Society and the Society For Biomaterials. Ratner has served as president of AIMBE, 2002-2003. In 2002, Dr. Ratner was elected a member of the National Academy of Engineering, USA. His research interests include biomaterials, tissue engineering, polymers, biocompatibility, surface analysis of organic materials, self assembly, nanobiotechnology and RF-plasma deposition.

  • Giuseppe Remuzzi, M.D., F.R.C.P, Head of Nephrology and Dialysis and Chairman of the Department of Transplantation at Bergamo Hospital, Director of The Negri Bergamo Laboratories of The Mario Negri Institute for Pharmacological Research in Bergamo, Italy

    Dr. Remuzzi is the Head of Nephrology and Dialysis and Chairman of the Department of Transplantation at Bergamo Hospital and head of the Negri Bergamo Laboratories, which is devoted to the study of renal disease and a center that he has directed since 1984. As a recognized leader in the field of kidney regeneration, Dr. Remuzzi recently authored a review article in the prestigious medical journal, The Lancet, on the field of kidney regeneration. As director of the Negri Bergamo Laboratories and the affiliated Clinical Research Center for Rare Diseases, both divisions of the Mario Negri Institute for Pharmacological Research, Dr. Remuzzi leads a diverse team of researchers studying human renal diseases and their corresponding experimental models from the perspective of pathophysiology and therapeutic intervention. Dr. Remuzzi’s work and research has helped drive major advances in many areas of nephrology, including transplant immunology and tolerance. Dr. Remuzzi completed his medical training at the University of Pavia and received specialty training in Hematology and Nephrology at the University of Milan. He has been awarded honorary memberships of the Association of American Physicians and the British Royal College of Physicians and has authored and co-authored more than 1,000 scientific articles, reviews and monographs.

  • Alan B. Retik, M.D., Chief of Pediatric Urology & Surgeon in Chief, Children's Hospital Boston

    Dr. Retik has been Chief of Pediatric Urology for 27 years at Children's Hospital Boston and is also Surgeon-in-Chief. Dr. Retik received a B.A. from Cornell University and an M.D. from Cornell Medical School. He trained at Peter Bent Brigham Hospital and Harvard Medical School. He also worked as a research fellow in the laboratory of Dr. Joseph E. Murray, recipient of the Nobel prize in medicine for his primary work in kidney transplantation. Dr. Retik was also involved in cancer research for two years at the National Cancer Institute in Bethesda Maryland. Dr. Retik undertook further specialization in pediatric urologic surgery at the Hospital for Sick Children in London. Dr. Retik has held numerous leadership positions including Chairman of the Section on Urology of the American Academy of Pediatrics, President of the Society for Pediatric Urology of the American Urological Association, and President of the New England Section of the American Urological Association. He has been a visiting professor at more than 100 institutions nationally and internationally. His bibliography comprises over 350 contributions to scientific literature, including editorship of several texts. He has been one of the primary editors of the last three editions of Campbell's Urology. In recognition of his academic achievements and leadership qualities, he was promoted to the rank of Professor of Surgery (Urology) by Harvard Medical School in 1981. He has been awarded the Pediatric Urology Medal from the American Academy of Pediatrics and the Ferdinand C. Valentine Medal from the New York Academy of Medicine.

  • Mark P. Schoenberg, M.D., Professor & Director of Urologic Oncology, Brady Urological Institute, Johns Hopkins

    Dr. Schoenberg has been Director of Urologic Oncology at the Brady Urological Institute at The Johns Hopkins Hospital since 1998. He also serves as Professor of Urology and Oncology. Dr. Schoenberg's main academic focus and area of clinical activity is the treatment of patients with bladder cancer. Dr. Schoenberg is involved in both basic and clinical research on the detection and management of patients with all forms of bladder cancer. His particular areas of clinical interest are the surgical treatment of invasive tumors and lower urinary tract reconstruction in both male and female patients. Dr. Schoenberg is the author or co-author of nine books and ninety journal articles. Since 2003, he has been Senior Editor of Seminars in Urologic Oncology. After receiving his MD from the University of Texas, Dr. Schoenberg underwent postgraduate training at the University of Pennsylvania and Johns Hopkins.

  • William D. Schwieterman, M.D., President and Founder, Tekgenics, Inc.

    Dr. Schwieterman is President and Founder of Tekgenics Inc., a consultancy company that provides clinical, regulatory, and general scientific advice to pharmaceutical and biotechnology companies. Dr. Schwieterman is an expert in the design of clinical trials for a wide range of therapeutic agents, including in the areas of regenerative medicine and tissue repair. Prior to his work at Tekgenics, Dr. Schwieterman served for ten years at the FDA (CBER) where he was a senior supervisor overseeing product development for numerous biological therapies. He was instrumental at FDA in generating one of the first guidance documents for sponsors of manipulated autologous structural cell therapies, and helped lay the foundation at FDA for how these products were to be both regulated and reviewed. He also supervised the development of biological therapies for the treatment of organ transplantation, skin replacement, and regenerative nasal repair, in addition to other work overseeing the development of new therapies for cytokines, gene therapy, and monoclonal antibodies for dozens of different diseases. Prior to joining FDA Dr. Schwieterman was a senior staff fellow at the National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) at NIH, where he did both scientific and clinical work in the area of systemic lupus erythematosus, and a fellow at the National Cancer Institute where he worked to advance the understanding of immunodeficiency disorders. He is a member of the American College of Rheumatology and the Regulatory Affairs Professional Society. He is trained in Rheumatology (NIAMS) and boarded in Internal Medicine (Mt. Sinai Hospital, New York City). Dr. Schwieterman received both his M.D. and B.S. from the University of Cincinnati.